Lundbeck receives "complete response" from FDA for its schizophrenia drug
This article was originally published in Pharmaceutical Approvals Monthly
FDA sends Lundbeck a "complete response" letter for its schizophrenia agent Serdolect (sertindole), reaching the same conclusion as its advisory committee: the atypical antipsychotic could be approved if Lundbeck can identify an appropriate patient population. Sertindole is clearly efficacious, but it also clearly has significant cardiovascular risk. The letter, announced June 25, requested "additional data to best understand the appropriate patient population for which Serdolect could be made available." At its April 7 review, the Psychopharmacologic Drugs Advisory Committee voted that, despite its lack of safety, the antipsychotic could be used in an acceptably safe manner in some patient groups (1"The Pink Sheet," April 13, 2009). But the panel couldn't pinpoint who those patients are, and so far neither can Lundbeck and FDA. Serdolect's user fee date was May 15
You may also be interested in...
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.
Head & Shoulders airing a 30-second TV spot featuring Kansas City Chiefs quarterback Patrick Mahomes and former Pittsburgh Steelers safety Troy Polamalu competing over who gives “100%” effort in everything they do.